Clinical trial NCT05361954: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Official title: A Phase 1b, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients With Relapsed or Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Cancer
Cancer of Pancreas
Sarcoma
Hepatic Metastasis
Solid Tumor
Keywords: Cancer
solid tumor
hepatic metastasis
Lead sponsor: Sorrento Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2022-05-05
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).

Detailed description: This is a Phase 1b, dose-ascending study to assess the safety, tolerability and recommended phase 2 dose (RP2D) of STI-1386 in subjects with relapsed and refractory solid tumors (RRSTs). STI-1386 is a second generation oncolytic virus.

This is a two-stage study, the first stage uses a single ascending dose, followed by the multiple ascending dose stage.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed extracranial solid tumors that are relapsing or refractory including locally advanced pancreatic cancer, unresectable soft tissue sarcomas, hepatic metastases due to colorectal cancer
* At least one measurable disease per Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1) with a non-nodal lesion with longest diameter ≥ 10 mm or nodal lesions with short diameter ≥ 15 mm
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
* As assessed by the investigator, ≥ 3 month life expectancy
* Adequate hematologic, liver and renal function at Screening as determined by lab criteria
* Recovered \< Grade 2 from all acute toxicities from previous therapy
* Has not had prior treatment with high dose corticosteroids within the 2 weeks of screening
* Is willing and able to comply with the study schedule and other protocol requirements
* Willing to follow contraception guidelines

Exclusion Criteria:

* Have a primary brain tumor
* Use of an investigational drug or local therapy or agent within 2 weeks of first dose of study drug. Current systemic chemotherapy per investigator's discretion is allowed, but no immune checkpoint inhibitors or immune modulators
* Use of anticoagulants or anti-platelet agents unless subject can safely start/stop to allow intratumoral injections
* Use of bevacizumab (Avastin) within 28 days of the STI-1386 injection
* Diagnosis of other malignancies that have required therapy in the last year or are not in complete remission. Exceptions include non-metastatic basal cell or squamous cell carcinomas of the skin, prostate cancer or cancer in situ that does not require treatment currently or is otherwise under control
* Requiring chronic systemic immunosuppressants, including steroids \> 20 mg/day
* Presence of bulky disease defined as any single mass \> 5 cm in greatest dimension will trigger a discussion to determine eligibility
* New York Heart Association (NYHA) Class \>3 of left ventricular ejection fraction (LVEF) \< 50%
* Prolonged corrected QT interval as determined by 12-lead electrocardiogram
* Has spinal cord compression or clinically unstable brain metastases within 4 weeks of first dose of study drug
* Evidence of active herpes infection and/or chronic herpes infection requiring prophylactic antiviral medication that may not be discontinued
* Has an active or recent COVID-19 infection, must have a negative RT-PCR test and not have had symptoms within 4 weeks of day 1 of study drug administration
* Any active infection requiring systemic therapy within 72 hours of injection of STI-1386, excluding anti-viral maintenance therapy for HIV
* Moderate to severe chronic obstructive pulmonary disease or other moderate to severe chronic respiratory conditions unless under treatment and stable for the 3 months of screening
* Have active human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia
* Pregnant or lactating or up to 3 months post last dose
* Underlying medical conditions that, in the opinion of the investigator and/or medical monitor will prevent the subject from participating
* Allergy to acyclovir and related anti-HSV antiviral agents

Primary outcomes:
measure: Incidence of adverse events (AEs)
timeFrame: baseline through study completion at up to approximately 29 months
measure: Incidence of immune-related adverse events (IrAEs)
timeFrame: baseline through study completion at up to approximately 29 months
Secondary outcomes:
measure: Preliminary Efficacy of STI-1386
timeFrame: baseline through study completion at up to approximately 29 months
measure: Measuring Pharmacokinetic [PK] Profile
timeFrame: baseline through study completion at up to approximately 29 months
measure: Assess immunoglobulin levels
timeFrame: baseline through study completion at up to approximately 29 months
Other outcomes:
Locations:
Study officials:
affiliation: Sorrento Therapeutics, Inc.
name: Mike Royal, MD
role: STUDY_DIRECTOR
References: